

Chemical Profile and Hepatoprotective Activity of Ethyl Acetate Extracts of *Euphorbia paralias* and *Euphorbia geniculata* (Euphorbiaceae) from Egypt

Afaf E. Abdel Ghani¹, Sayed A El-Toumy², Wagdi I. A. El-DougDoug², Ahmed M. Mansour², Wafaa H. B. Hassan², Hanaa M. Hassan^{3,*}

Afaf E. Abdel Ghani¹, Sayed A El-Toumy², Wagdi I. A. El-DougDoug², Ahmed M. Mansour², Wafaa H. B. Hassan², Hanaa M. Hassan^{3,*}

¹Department of Pharmacognosy, Faculty of Pharmacy, Zagazig University, 44519 Zagazig, Egypt.

²Chemistry of Tannins Department, National Research Centre, 12622 Dokki, Cairo,

³Department of Organic Chemistry, Faculty of Science, Banha University, 13518 Banha, Egypt.

⁴Department of Pharmacology and Toxicology Faculty of Pharmacy, El-Alzhar University Cairo, Egypt.

⁵Department of Pharmacognosy Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.

⁶Pharmacy Department Banha Educational Hospital, 13518 Banha, Egypt.

Correspondence

Hanaa M Hassan

Pharmacy Department Banha Educational Hospital, 13518, Banha, Egypt.

E-mail: hanaazain111@yahoo.com

History

- Submission Date: 11-02-2020;
- Review completed: 03-03-2020
- Accepted Date: 25-03-2020.

DOI : 10.5530/pj.2020.12.109

Article Available online

<http://www.phcogj.com/v12/i4>

Copyright

© 2020 Phcogj.Com. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

ABSTRACT

Background: Plants belonging to the genus *Euphorbia* were used traditionally to treat several health disorders and diseases. **Objective:** the aim of this study is evaluation of secondary metabolites and hepatoprotective activity of the ethyl acetate fractions of the aerial parts of *Euphorbia paralias* (*Ep*) and *Euphorbia geniculata* (*Eg*). **Materials and Methods:** UPLC-ESI-MS/MS technique was used for identification of the secondary metabolites. The hepatoprotective potential of the two plants was evaluated for the first time in male rats with thioacetamide induced liver injury. **Results:** A total of 32 secondary metabolites were identified in the ethyl acetate fractions of the aerial parts of both species. Ellagitannins such as tetragalloyl hexoside, ellagic acid, gallic acid, and flavonoids such as kaempferol-3-*O*- β -(6''-galloyl-*O*-glucopyranoside), quercetin glycosides (glucoside and arabinoside) were found to be the major components in *Ep* whereas flavonoid glycosides including quercetin rutinoside, quercetin glycosides (glucoside, arabinoside and rhamnoside) and kaempferol glycoside derivatives were highly abundant in *Eg*. Administration of thioacetamide resulted in marked elevation in liver enzymes, elevation of lipid profile and alteration in oxidative stress parameters. While pretreatment of rats with *Ep* and *Eg* ethyl acetate fractions significantly attenuated the hepatic toxicity through reduction of liver biomarkers, improving the redox status of the tissue and so brought down the serum biochemical parameters and lipid profile nearly toward the normal levels. **Conclusion:** The studied fractions show hepatoprotective potential with promising value as hepatoprotective drugs of natural origin in comparison with silymarin as the standard hepatoprotective drug.

Key words: *Euphorbia*, UPLC-ESI-MS/MS, Polyphenolics, Hepatoprotective.

INTRODUCTION

Plants have used as an essential source of drugs and remedies on treatment of diseases and health disorders since ancient times¹. Flavonoids and phenolic compounds containing plants which are common among medicinal plants were reported for its various health benefits and applications. They have a wide spectrum of pharmacological activities including anti-inflammatory, antioxidant, hepatoprotective, anticancer and antimicrobial activities. They also decrease the risk of cardiovascular diseases, enhance regeneration of the liver and increase life expectancy^{2,3}. As liver damage can be life threatening and its damage is caused by several factors such as alcohol, viruses, organic chemicals, metabolic and genetic abnormalities⁴. Liver transplantation was improved survival rate of patients in some cases only and is limited to a small number of patients due to non-availability of suitable donors. And so, finding new drugs that are able to enhance liver regeneration and prevent liver failure is a very important need. Natural products as plant extracts exhibiting antioxidant and hepatoprotective activities can be useful in these needs². The aim of the current study was to identify the polyphenolics and flavonoids in the

ethyl acetate (EA) fractions of the aerial parts of *Ep* and *Eg* using UPLC-ESI-MS/MS and to investigate the possible hepatoprotective activities of the studied fractions.

MATERIALS AND METHODS

Plant material and extraction

Aerial parts of *E. paralias* L. and *E. geniculata* Ortega were collected in the flowering stage on May and August 2015, respectively. *E. paralias* was collected from the North beach of Alexandria, Egypt. While *E. geniculata* was collected from roadsides in the vicinity of Banha, Qalubya, Egypt. The identification was kindly verified by Dr. Ahmed Abd El-Razik Lecturer of Plant Taxonomy, Department of Botany, Faculty of Science, Banha University, Egypt. The vouchers specimens (no. S303 and S304) were deposited in National Research Centre, Dokki, Cairo, Egypt. The air-dried powdered plant materials *Ep* and *Eg* (500 g of each plant) were extracted by cold maceration with 70 % methanol until complete exhaustion. The methanolic extracts were evaporated under reduced pressure at 45°C. The greenish brown viscous residues (105.0 and 100.5 gm respectively) were separately dissolved in MeOH-H₂O mixture

Cite this article: Ghani ASA, El-Toumy SA, El-DougDoug WIA, Mansour AMI, Hassan WHB, Hassan HM. Chemical Profile and Hepatoprotective Activity of Ethyl Acetate Extracts of land *Euphorbia geniculata* (Euphorbiaceae) from Egypt. Pharmacogn J. 2020;12(4):762-70.

(500 ml, 1:9 v/v) and subjected to fractionation with dichloromethane then by ethyl acetate to afford ethyl acetate fractions (18.5 and 9.2 gm) of *Ep* and *Eg*, respectively.

UPLC-ESI-MS/MS

The sample (100 µg/ml) solution of each fraction (ethyl acetate fractions of *E. p.* and *E. g.*) were prepared using high performance liquid chromatography (HPLC) analytical grade solvent of MeOH, filtered using a membrane disc filter (0.2 µm) then subjected to LC-ESI-MS analysis. Samples injection volumes (10 µl) were injected into the UPLC instrument equipped with reverse phase C-18 column (ACQUITY UPLC-BEH C18 1.7 µm particle size- 2.1×50 mm column). Mobile phase elution was made with the flow rate of 0.2 ml/min using gradient mobile phase comprising two eluents: eluent A is H₂O acidified with 0.1 % formic acid and eluent B is MeOH acidified with 0.1 % formic acid. Elution was performed using the following gradient: 20 % B, 0-1 min; 20-90 % B, 1-18 min; 20 % B, 18-20 min. Mass spectra were detected in the ESI negative ion mode between *m/z* 50-900 at 30 eV capillary conc. and capillary voltage 3 KV. The peaks and spectra were processed using the Maslynx 4.1 software and tentatively identified by comparing its retention time (*Rt*) and mass spectrum with reported data. For fragmentation collision energy 40 eV was used.

Hepatoprotective materials

Animals

Male Sprague Dawley rats weighting (220±5 g) and Balb C mice (20-25 g) were purchased from Theodor Bilharz Institute (Giza, Egypt). The animals were housed in the animal facility of Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt. They were fed with standard diet pellets (El-Nasr Company, Abou-Zaabal, Cairo, Egypt), and allowed free access to water. The animals were kept at room temperature (25°C±2.0) and natural humidity (it was 55%) with 12 h-light/12 h dark cycle. The experiments were conducted in accordance with the ethical guidelines for investigations in laboratory animals and comply with the guidelines for the care and use of laboratory animals. The approval committee was given by ZU-IACUC committee with approval number ZU-IACUC/3/F/145/2019.

Chemicals

Silymarin (Sil): it was purchased as yellow fine powder and dissolved in normal saline, from Sigma-Aldrich Chemical Company, St. Louis, MO, USA. Thioacetamide (TAA): was purchased as powder purity (98.1 %) then dissolved in normal saline, from Sigma-Aldrich Chemical Company, St. Louis, MO, USA.

Acute toxicity or lethality (LD₅₀) test

To assess for *Ep* and *Eg* extracts safety margin, the lethality test (LD₅₀) was carried out by estimation of acute toxicity monitored in animals. Ethyl acetate fractions of *Ep* and *Eg* were dissolved in dist. water at the mentioned doses below. The (LD₅₀) was estimated in mice by oral intake according to OECD guidelines No. 420. At a preliminary test, the mice were divided into three groups each of 12 animals and each animal received one dose of 5000 mg/kg body weight of the mice. Animals were kept under observation for 24 h for any signs of toxicity or cases of deaths. Control animals received the vehicle (normal saline) and were kept under the same conditions without any treatment. Toxicity signs and number of deaths for each extract during 24 h were recorded and the LD₅₀ was calculated as the geometric mean of the dose. The results obtained showed no lethality.

Antifibrotic effect

Ethyl acetate fractions of *Ep* and *Eg* were dissolved in dist. water at the required doses, forty eight rats were divided into eight groups, six animals each, and the following schedule of treatment was adopted: **Group**

1 (Control group): rats were given normal saline daily (2 ml/kg b.w., orally) for 4 consecutive weeks and served as negative control group. **Group 2 (TAA):** rats were injected intra-peritoneal with TAA (200 mg/kg b.w.) dissolved in saline three times weekly for 4 consecutive weeks. **Group 3 (Sil):** rats were treated with silymarin orally (50 mg/kg b.w.) dissolved in normal saline daily for 4 consecutive weeks. **Group 4 (Ep):** rats were administered *Ep* fraction orally (200 mg/kg b.w.) dissolved in normal saline daily for 4 consecutive weeks. **Group 5 (Eg):** rats were treated with *Eg* ethyl acetate fraction orally (200 mg/kg b.w.) dissolved in normal saline daily for 4 consecutive weeks. **Group 6 (Sil+TAA):** rats were pretreated orally with silymarin then with thioacetamide daily for 4 consecutive weeks. **Group 7 (Ep+TAA):** rats were pretreated orally with *Ep* ethyl acetate fraction then with thioacetamide daily for 4 consecutive weeks using the same dose schedules as mentioned above. **Group 8 (Eg+TAA):** rats were pretreated orally with *Eg* ethyl acetate fraction then with TAA for 4 consecutive weeks using the same dose schedules as mentioned above, plants fractions and silymarin were administered to the animals orally by gastric intubation for 4 weeks following the procedure of (Dutta et al., 2013)⁵.

Serum and tissue preparations

Samples of blood were collected retro-orbital venous plexus of rats (under light ether anesthesia) in non-heparinized tubes and for measuring biochemical parameters; the sera were separated. Later the animals were sacrificed; liver was dissected, washed in saline, blotted between dry filter papers and kept until antioxidants and histopathological examinations.

Biochemical analysis

Serum separated from blood samples was used for the determination of liver enzymes aspartate aminotransferase (AST), alanine aminotransferase (ALT), cholesterol (CH), triglycerides (TG), high density lipoprotein (HDL), low density lipoprotein (LDL) and total bilirubin⁶. Part of liver tissue was homogenated and centrifuged at 5000 rpm for 10 min and the resulting supernatant was used for lipid peroxides malondialdehyde (MDA) contents, determination of oxidative enzymes; superoxide dismutase (SOD), catalase (CAT) activities, and reduced glutathione (GSH)^{7,8}. All tests were carried out using colorimetric spectrum Biodiagnosics™ and Diamond™ kits (Cairo, Egypt),

Histopathological examination

Autopsy samples were taken from the rats livers in the different groups and fixed in 10 % neutral buffered formalin for 24 h. Then serial dilutions of alcohol (ethyl, absolute ethyl and methyl) were used in specimens' dehydration. The specimens were cleaned by xylene and embedded in paraffin in a hot air oven at 56°C for 24 h. Paraffin bees wax tissue blocks were prepared for sectioning at 4 µm thicknesses by sledge microtome. The obtained sections of tissue were embedded between glass slides, deparaffinized, stained by hematoxylin and eosin stain, and another slides from the same samples stained with a specific stain (Masson's trichrom) then all were examined using the light electric microscope⁹.

Statistical analysis of data

All data are presented as mean±SEM. Statistical analysis was performed using GraphPad prism version 7 (GraphPad, San Diego, CA). Group differences were analyzed using one-way analysis of variance (ANOVA) followed by Tukey-Kramer for multiple comparison tests. The difference was considered significant at $P \leq 0.05$.

RESULTS

UPLC-ESI-MS/MS identification of secondary metabolites

Structural analysis of different compounds found in the aerial parts of *Ep* and *Eg* ethyl acetate fractions resulted in the separation and tentative

identification of 32 compounds using UPLC-ESI-MS/MS. Identification of compounds was performed using (M-1)⁺/MS² and comparison with reported data. Ellagitannins and phenolic acids (22.00 and 11.48 %), flavonoids such as quercetin glycosides (35.00 and 39.97 %) and kaempferol glycosides (20.00 and 3.44 %) were found to be the major components in *Ep* and *Eg*, respectively; as ellagitannins (tetragalloyl hexoside, ellagic acid, gallic acid) and flavonoids (kaempferol-3-*O*-β-(6''-galloyl-*O*-glucopyranoside, quercetin glycosides (glucoside and arabinoside) were found to be the major components in *Ep* while quercetin rutinoside and other quercetin glycosides (glucoside, arabinoside and rhamnoside) were highly abundant in *Eg*. As observed; molecular and fragment ions were listed in Table 1. LC-MS/MS profiles for *Ep* and *Eg* ethyl acetate fractions in the negative ion mode are shown in (Figure 1).

Identification of tannins

Peak 1 with deprotonated molecular ion peak at *m/z* 787 [M-H] and MS² at *m/z* 635, 483, 331, 169, so it was tentatively identified as tetragalloyl hexoside¹⁰. While peak 2 was tentatively identified as gallic acid as its deprotonated molecular ion peak at *m/z* 169 [M-H] and MS² at *m/z* 125 (M-H-COOH)¹⁰. Peak 5 with molecular ion peak at *m/z* 183 [M-H] while MS² at *m/z* 125, so it was tentatively identified as methyl gallate¹⁰. Peak 24 showed a molecular ion peak [M-H] at *m/z* 301, and MS² fragmentations at *m/z* 151, 211 so it was identified as ellagic acid¹¹. Peaks 8 and 10 with deprotonated molecular ion peak at *m/z* 635 [M-H] and MS² at 483 [M-H-galloyl-H₂O], 331 (M-H-2 (galloyl - H₂O)), 169 (M-H-hexoside-2 (galloyl-H₂O)), so they were tentatively identified as trigalloyl hexoside and its isomer respectively¹¹.

Table 1: Compounds identified in the ethyl acetate fractions of *E. paralias* and *E. geniculata* by using UPLC ESI-MS/MS in negative ionization mode.

No	RT min	(M-H) M/z	MS ² /MS fragment ions	Expected compounds	Ep %	Eg %	Ref
1	0.8	787	635, 483, 331, 183, 168.9	Tetragalloyl- <i>O</i> -hexoside	6	1.52	10
2	1.5	169	125	Gallic acid	6	1.07	15
3	3.5	585	271(100 %)	Nargarin-galloyl-hexoside	+	-	12
4	4.4	463	301(100 %)	Quercetin-3- <i>O</i> -glucoside	+	+	
5	5.2	183	151, 125	Methyl gallate	6	2.6	10
6	6.2	353	191, 179	Chlorogenic acid	+	1.07	12
7	6.3	615	463, 301(100 %), 152, 125	Quercetin-galloyl-hexoside	+	-	10
8	6.5	635	465, 331, 169	Tri-galloyl-hexoside	+	0.46	10
9	6.9	635	635, 431, 285	Kaempferol-rhamn.-acetyl-glu isomer.	2	1.44	16
10	7.1	635	331, 169	Trigalloyl hexoside isomer	-	1.75	10
11	7.5	461	299	Diosmetin hexoside	+	-	
12	7.7	433	301(100 %)	Quercetin xyloside	+	-	
13	8.3	325	193	Ferulic acid pentoside	-	+	
14	8.4	461	285	Kaempferol-glucuronide	+	-	15
15	8.7	599	447, 285, 169	kaempferol-3- <i>O</i> -β-(6''-galloyl- <i>O</i> - glu)	15	+	
16	9.1	431	285 (100 %)	Kaempferol rhamnoside	+	-	
17	9.2	651	609, 447, 301(100 %)	Quercetin-cetyl-hexoside- rhamnoside	-	+	13
18	9.34	927	927, 463, 301, 151	Quercetin-3- <i>O</i> -glucopyranoside	28	6.25	14
19	9.8	433	433, 301, 151	Quercetin-3- <i>O</i> -arabinoside	7	8.58	10
20	9.9	615	463, 301 (100 %)	querectin-galloyl glucopyranoside	-	+	16
21	10.0	609	301, 447(100 %),	Quercetin-rutinoside (rutin)	-	8.74	10
22	10.2	447	301, 447, 609	Quercetin-3-rhamnoside	-	16.4	13
23	10.4	447	447, 285	Kaempferol-3- <i>O</i> -glucopyranoside	3	+	10
24	11.8	301	211, 151	Ellagic acid	4	2	11
25	11.9	431	285, 255	Kaempferol rhamnoside	-	+	10
26	13.4	609	299 (100 %)	Diosmetin derivative	-	+	13
27	13.6	651	547 [M-104], 427 [M-104-120], 301 [M-350]	Quercetin-3-rhamnoside-acetyl hexoside	-	+	
28	18.4	635	285 (100 %), 227, 241	Kaempferol-rhamnosyl-acetyl glucoside	-	+	10
29	23.7	301	151	Quercetin	+	+	
30	23.4	285	151, 125	kaempferol	-	+	
31	12.8	329	269	Dimethoxy apigenin	+	-	13
32	26.4	329	314 [M-CH ₃], 299 [M-2CH ₃], 271 [M-2CH ₃ -CO]	Diosmetin dimethyl ether	+	-	

Identification of phenolic acids and their derivatives

Peak 6 with deprotonated molecular ion peak at m/z 353 [M-H] and MS² at m/z 191 (M-H-caffeoyl, 161) and 179 (M-H-quinic) so it was tentatively identified as chlorogenic acid¹². Peak 13 with deprotonated molecular ion peak at m/z 325 (M-H), and MS² at m/z 193 (M-H-arabinose) so it was tentatively identified as ferulic acid pentoside¹⁰.

Identification of flavonoid compounds

Many flavonoid glycosides were identified in the ethyl acetate fractions of *Ep* and *Eg* where peak 3 detected at m/z 585 [M-H] with daughter ions at m/z 271, 100 % so it was attributed to naringenin-galloylglucoside¹³. Peaks 4, 7, 12, 17-22, 28 and 31 all identified as quercetin derivatives as they have quercetin moiety (301 amu) at all, they are different in types of sugar moieties according to the m/z lost during fragmentation process as (-glucose or galactose, -162), (-rhamnose, -146), (-xylose or arabinose, -132) and (-acetyl glucose, -206) and some of which identified as galloyl glycoside due to lose of galloyl moiety (-152) as shown in table (1).^{10,13,14} As the same were peaks 9, 14-16, 23, 25, 29 and 30 were identified as kaempferol derivatives due to presence of kaempferoyl moiety (285 amu); In addition to sugars moieties and galloyl moiety as shown in table (1).^{10,15,16} Peak 11 identified as diosmetin-hexoside to presence of molecular ion peak at m/z 461, [M-H] and MS² fragments at 299 amu corresponding to diosmetin moiety (M-H- 162)¹³. Peak 32

identified as dimethoxy apigenin due to molecular ion peak at 329 m/z and daughter ion at 269 amu¹³.

Hepatoprotective

Thioacetamide is hepatotoxic agent known to induce acute or chronic liver disease (fibrosis and cirrhosis) in the experimental animal model¹⁷. In the present work, TAA is used as potent hepatotoxic agent in rats. A dose of 200 mg/kg ip TAA administration is reported to be the cause of hepatic toxicity. Its effect is due to increased oxidative stress¹⁸.

Acute toxicity or lethality (LD₅₀) test

The results showed that the animals survived during the 24 h observation and no visible signs of toxicity were observed. According to Hodge and Sterner toxicity scale¹⁹, the LD₅₀ values of the two fractions were in the practically non-toxic categories.

Antifibrotic effects

Evaluation of liver biochemical parameters

Exposure of animals with the hepatotoxic agent, TAA resulted in significant ($p \leq 0.05$) increase in the liver enzymes (ALT and AST) and total bilirubin in serum, lipid profiles (CH, TG and LDL) and lipid peroxidation (MDA) while significant decrease in HDL, GSH,




Figure 1: UPLC-ESI-MS/MS chromatogram of ethyl acetate fractions of *E. paralias* L. (A) and *E. geniculata* Ortega (B) in negative mode.




Figure 2: The effect of *E. paralias*, and *E. geniculata* on thioacetamide-treated rats in A: Alanine aminotransferase, B: Aspartate aminotransferase and C: Total bilirubin level on comparison with silymarin effect.




Figure 3: The effect of *E. paralias*, and *E. geniculata* on thioacetamid-treated rats on A: Cholesterol, B: triglycerides C: low density lipoprotein D: High density lipoprotein mg/dl in thioacetamid-treated rats on comparison with Silymarin.




Figure 4: The effects *E. paralias*, and *E. geniculata* A: on malondialdehyde, B: On reduced glutathione C: On catalase activity and D: On superoxide dismutase in thioacetamide-treated rats on comparison with Silymarin.

CAT and SOD), indicative of hepatocytes damage.⁸ Pretreatment of experimental animals with (*Ep* and *Eg*) EA fractions reversed the TAA-induced hepatotoxicity and restored the elevated levels of liver biomarkers toward normality in comparison with silymarin treated group as follow; *Ep*, *Eg* and silymarin caused significant decrease in the liver enzymes (ALT, AST and total bilirubin in serum) (Figure 2), lipid profiles (CH, TG and LDL) (Figure 3) and lipid peroxidation (MDA) while significant increase in HDL, GSH, CAT and SOD (Figure 4).

Histopathological results

Histopathological examinations of the sections of rat liver exposed to TAA showed (in H and E staining) severe tissue damage and hepatocytes degeneration. *Ep* and *Eg* pre-treatment attenuated the hepatic injury and showed significant protection of the hepatic cells from damage. There were no such alterations in *Ep* and *Eg* groups in compared to normal and silymarin treated groups (Figures 5 and 6).

DISCUSSION

The liver is the largest gland in the human body and susceptible to almost many different diseases including hepatitis, cirrhosis, alcohol related disorders and liver cancer. A major cause of these disorders is due to exposure to different environmental pollutants and xenobiotics²⁰. Also, the exposure to a lot of chemicals, such as carbon tetrachloride, bromobenzene, ethanol, thioacetamide and polycyclic aromatic hydrocarbons have been implicated in the etiology of liver diseases²¹. It is fundamentally known that the regulation of apoptosis is a potential mechanism through which many agents such as polyphenolic compounds; can prevent toxicity and carcinogenesis²². Silymarin is a mixture of natural flavanolignans contains at least seven compounds²³. The hepatoprotective and antioxidant activities of silymarin were attributed to control free radicals (FR), produced by the hepatic metabolism of toxic substances²⁴. The present study revealed that both *Ep* and *Eg* contain several types of gallotannins, phenolic




Figure 5: Light photomicrograph of H & E stain of liver sections tissues as A: (Cont gp): showing average central vein (CV), and hepatocytes arranged in single cell cords (black arrow) with intervening blood sinusoids. B: (TAA-gp): mildly expanded portal tract with mild portal and peri-portal inflammatory infiltrate (black arrows) and scattered apoptotic hepatocytes in peri-portal area (yellow arrow). C: (Sil+TAA gp): average central vein with apoptotic hepatocytes in peri-venular area (black arrows) D: (*Ep*+TAA gr): average portal tract with average portal vein (PV) and average hepatocytes in peri-portal area (black arrow) E: (*Eg*+TAA gp): dilated central veins, and scattered apoptotic hepatocytes in peri-venular area (black arrow) (×400 except D×200).




Figure 6: light photomicrograph Masson's trichrome as: A: (Cont gp): liver section showing average collagen distribution in portal tract (black arrows). B: (TAA gp): excess collagen bundles with complete nodule formation (black arrow). C: (Sil+TAA gp): high power view showing excess collagen in portal tracts with fibrous septa extending into hepatic lobule (yellow arrow). D: (*Ep*+TAA gp): average collagen around central vein (black arrow). E: (*Eg*+TAA gp): average collagen in portal tracts (black arrow) (×400).

acids and flavonoids which tentatively identified through UPLC-ESI-MS/MS analysis of ethyl acetate fractions of *Ep* and *Eg*. Polyphenolic compounds including flavonoids constitute 77.10 and 51.51 % of the ethyl acetate fractions of *Ep* and *Eg*, respectively. Quercetin and its derivatives in *Eg* (39.97 %) represent about twice the kaempferol compounds in *Ep* (20.00 %). These compounds were known to have high antioxidant activity that attributed to their ability to control FR demonstrated by high hepatoprotective activity in comparison with standard drug silymarin^{25,26}. That was evidenced by the significant improvement of liver enzymes (ALT and AST), total bilirubin, lipid peroxidation (MDA), oxidative stress related parameters (CAT, GSH and SOD) and lipid profile (CH, LDL, TG and HDL). According to the study; the potency strength of the fractions and silymarin on the liver enzymes differs from one to other; *Ep*+TAA gp show more improvement in ALT and CH, than *Eg*+TAA gp but nearly equal to

Sil+TAA gp, while *Eg*+TAA gp show more improvement in GSH and CAT in comparison with Sil-gp but the both plant fractions were equally in improvement degree in the rest of liver enzymes. Histopathologically, parallel structural improvement was elicited by either plants extracts as compared to silymarin. This is evidenced by the views of rat's liver tissues treated with both plants as showing no collagen aggregation around central veins, no inflammatory infiltrate and no fibrosis. The results of the study on liver were indicating the promising values of these plants as hepatoprotective herbs in the future with more flow up.

CONCLUSIONS

This study revealed the identification of 32 polyphenolic compounds in the ethyl acetate fractions of the *Ep* and *Eg* using UPLC-ESI-MS/MS analysis; mainly tannins and flavonoid glycosides. Hepatoprotective activity exhibited by the studied extracts might be attributed to the high

content of these compounds. These findings need more explored and investigated through further set of experiments to recommend the ethyl acetate extracts of the two plants as hepatoprotective drugs of natural origin.

ACKNOWLEDGEMENTS





The authors would like to thank Dr. Ahmed Abdel Razik respective Lecturer of Plant Taxonomy, Department of Botany, Faculty of Science, Banha University, Banha, Egypt; for plants identification and supply.

REFERENCES

- Dias DA, Urban S, Roessner U. A historical overview of natural products in drug discovery. *Metabolites* 2012;2(2):303-36.
- Van Wyk B-E, Wink M. *Phytomedicines, herbal drugs and poisons*. University of Chicago Press, Chicago; 2015.
- Van Wyk B-E, and Wink M., *Medicinal plants of the world*. 2nd Ed, Pretoria: Briza; 2017.
- Robin S, Sunil K, Rana AC, Nidhi S. Different models of hepatotoxicity and related liver diseases: a review. *International Research Journal of Pharmacy*. 2012;3(2):86-95.
- Dutta B, Lahkar M, Bibin BA, Lihite M. Hepatoprotective activity of *Tamarind indica* and *Homalomena aromatica* in rats. *International Journal of Pharmacy and Pharmaceutical Science*. 2013;5(2):436-8.
- Maheshwari N: *Clinical Biochemistry*. 1st Ed., Jaypee Brothers medical publishers. Ltd., India; 2008.
- Ramakrishnan S, Sulochana KN. *Manual of medical laboratory techniques*. 1st Ed., Jaypee Brothers Medical Publishers Ltd., India; 2012.
- Balahoroğlu R, Dülger H, Özbek, H, Bayram I, Şekeroğlu M. Protective effects of antioxidants on the experimental liver and kidney toxicity in mice. *European Journal of General Medicine*. 2008;5(3):157-64.
- Banchroft JD, Stevens A, Turner DR. *Theory and practice of histological techniques*, 4th ed. Churchill Livingstone, New York; 1996.
- Abu-Reidah M I, Ali-Shtayeh S M, Jamous M R, Arráez-Román D, Segura-Carretero A. HPLC–DAD–ESI-MS/MS screening of bioactive components From *Rhus coriaria* L. (Sumac fruits). *Food Chemistry*. 2015;166:179-91.
- Mena P, Calani L, Dall'Asta C, Galaverna G, García-Viguera C, Bruni R, et al. Rapid and Comprehensive Evaluation of (Poly)phenolic Compounds in Pomegranate (*Punica granatum* L.) Juice by UPLC-MSn. *Molecules*. 2012;17:14821-40.
- Oszmiański J, Nowicka P, Teleszko M, Wojdyło A, Cebulak T, Oklejewicz K. Analysis of Phenolic Compounds and Antioxidant Activity in Wild Blackberry Fruits. Poland. *International Journal Molecular Science*. 2015;16(7):14540-53.
- Brito A, Ramirez JE, Areche C, Sepúlveda B, Simirgiotis MJ. HPLC-UV-MS Profiles of Phenolic Compounds and Antioxidant Activity of Fruits from Three Citrus Species Consumed in Northern Chile. *Molecules Journal*. 2014;19:17400-21.
- Chen HJ, Inbaraj BS, Chen BH. Determination of Phenolic Acids and Flavonoids in *Taraxacum formosanum* Kitam by Liquid Chromatography-Tandem Mass Spectrometry Coupled with a Post-Column Derivatization Technique. *International Journal Molecular Science*. 2012;13:260-85.
- Pisano B M, Cosentino S, Viale S, Spanò D, Corona A, Esposito F, et al. Biological Activities of Aerial Parts Extracts of *Euphorbia characias*. *Italy BioMed Research International*. 2016;2016:11.
- Sobeh M, El-Hawary E, Peixoto H, Labib RM, Handoussa H, Swilam N, et al. Identification of phenolic secondary metabolites from *Schotia brachypetala* Sond. (Fabaceae) and demonstration of their antioxidant activities in *Caenorhabditis elegans*. *Peer Journal*. 2016;2404.
- Dwivedi DK, Jena GB. Glibenclamide protects against thioacetamide-induced hepatic damage in Wistar rat: investigation on NLRP3, MMP-2, and stellate cell activation. *Naunyn-Schmiedeberg's. Archives of Pharmacology*. 2018;391(11):1257-74.
- Aftab A, Pillai KK, Shibli JA, Balani DK, Najmi AK, Marwah R. Evaluation of the hepatoprotective potential of jigrine pre-treatment on thioacetamide induced liver damage in rats. *Indian Journal of Pharmacology*. 1999;3:416-21.
- Sandu RB, Tartău L, Miron A, Zagnat M, Ghiciuc CM, Lupuşoru CE. Experimental researches on acute toxicity of a *Bidens tripartita* extract in mice-preliminary investigations. *Revista Medico Chirurgicala a Societatii de Medici si Naturalisti din Lasi*. 2012;116(4):1230-4.
- Sreelatha S, Padma P, Umadevi M. Protective effects of *Coriandrum sativum* extracts on carbon tetrachloride-induced hepatotoxicity in rats. *Food and Chemical Toxicology*. 2009;47(4):702-8.
- Adesanoye OA, Farombi EO. Hepatoprotective effects of *Vernonia amygdalina* (Asteraceae) in rats treated with carbon tetrachloride. *Experimental and Toxicologic Pathology*. 2010;62(2):197-206.
- Srivastava A, Akoh CC, Fischer J, Krewer G. Effect of anthocyanin fractions from selected cultivars of Georgia-grown blueberries on apoptosis and phase II enzymes. *Journal of Agriculture and Food Chemistry*. 2007;55(8):3180-5.
- Morales-González JA, Gayosso-Islas E, Sánchez-Moreno C, Valadez-Vega C, Morales- González A, Esquivel-Soto J, et al. Protective effect of silymarin on liver damage by xenobiotics. In: *Oxidative stress and chronic degenerative diseases-a role for antioxidants*, editor. Rijeka: Croatia InTechOpen; 2013.
- Flora K, Hahn M, Rosen H, Benner K. Milk thistle (*Silybum marianum*) for the therapy of liver disease. *American Journal of Gastroenterol*. 1998;93:139-43.
- Afifi NA, Galal, MA, Ibrahim MK. Hepato-protective influence of quercetin and ellagic acid on thioacetamide-induced hepatotoxicity in rats. *Canadian Journal of Physiology and Pharmacology*. 2018;96(6):624-9.
- Yanqing Z, Dongjie Z, Changqing Yu, Chenghao J, Kihru I. Antioxidant and hepatoprotective activity of Kaempferol-3-O-β-D-(2,6-di-α-L-rhamnopyranosyl) galactopyranoside against carbon tetrachloride-induced liver injury in mice. *Food Science Biotechnology*. 2017;26(4):1071-6.

GRAPHICAL ABSTRACT

The effect of *E. paralias* And *E. geniculata* ethyl acetate Fractions on Change in Liver Enzymes in TAA-treated rats on Comparison with Silymarin Effect:



ABOUT AUTHORS



Prof. Dr. **Afaf El-sayed Ali Abdel Ghani** graduated in pharmaceutical sciences in 1981 and subsequently completed her MSc (1985) at University of Zagazig and PhD (1990) degree in Doctorate of philosophy through a channel system mission with the institute of pharmaceutical chemistry, Bonn University, Germany. Assistant Prof. (1998) in Pharmacognosy, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt. Professional in May 2005 as Prof. of pharmacognosy at Faculty of Pharmacy Zagazig University.



Prof. Dr. **Sayed El-Toumy** graduated in chemistry in 1984 and subsequently completed his MSc (1994) and PhD (1997) degrees in natural products at the Cairo University. He undertook post-doctoral at University of Leipzig, Institute of Pharmacy, Germany, (4-5-2002 to 26-4-2003). He was appointed as associate professor in 2005 and as full professor in 2011. His research interests are the isolation, identification and elucidation structure of polyphenolic compounds from folk medicinal plants using modern techniques and their application.



Prof. Dr. **Wagdy Ibrahim Ahamed Ali El-DougDoug** Prof. Dr. Wagdy Ibrahim Ahamed Ali El-DougDoug graduated in Special Chemistry in 1986 and subsequently completed his MSc in Organic Chemistry, Zagazig University (1991), and Ph.D. in Organic Chemistry, Zagazig University (1995). Assistant Professor in Organic Chemistry (2002) and professor in 2011. Head of Device of Organic Chemistry in 2015 until now in Chemistry Department, Faculty of Science, Banha University, Egypt. His position is Executive Director of Quality Assurance Faculty of Science, Banha, University (2013- Until now).



Prof. Dr. **Ahmed Mohamed Ibrahim Mansour** graduated in pharmaceutical sciences in 1991 and subsequently completed his MSc (1997) at **Faculty of Pharmacy, El Azhar University** and Ph.D. (2005) in Pharmacology, through channel system (Between Albert-Ludweege University, Freiburg, Germany and Pharmacology & Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt). Assistant Professor (2012) of Pharmacology & Toxicology, Faculty of Pharmacy, Al-Azhar University. Professor of Pharmacology & Toxicology (2017), Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt.



Prof. Dr. **Wafaa Hassan Badr Hassan** graduated in pharmaceutical sciences in 1989 and subsequently completed her MSc (1996) at University of Zagazig and PhD (2004) degree in Doctorate of philosophy in pharmacognosy through a full grant from Heinrich Heine University, Düsseldorf, Germany. Assistant Professor (2013) of pharmacognosy at Faculty of Pharmacy Zagazig University. Professional in 2019 as Prof. of pharmacognosy at Faculty of Pharmacy Zagazig University.



Hanaa Mohamed zain El-Abdin Hassan

Master Pharmacist on first degree in government Banha Hospital.
Bachelor of pharmacy Science: - 1996, Master degree in pharmaceutical sciences of pharmacognosy – 2012, from Zagazig, University, Zagazig, Egypt.

Cite this article: Ghani ASA, El-Toumy SA, El-DougDoug WIA, Mansour AMI, Hassan WHB, Hassan HM. Chemical Profile and Hepatoprotective Activity of Ethyl Acetate Extracts of land *Euphorbia geniculata* (Euphorbiaceae) from Egypt. Pharmacogn J. 2020;12(4):762-70.